Home › Acute Myeloid Leukemia › Kansas › Topeka
Acute Myeloid Leukemia clinical trials in Topeka, KS
3 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Topeka (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka
- Topeka VA Hospital, Topeka
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- University of Kansas Health System Saint Francis Campus, Topeka
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA40 studies
- Seattle, WA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA30 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in Topeka
- Steatotic Liver Disease7 studies
- Prostate Cancer7 studies
- Overweight7 studies
- Non-Small Cell Lung Cancer7 studies
- Obesity6 studies
- Breast Cancer6 studies
- Crohn's Disease6 studies
- Lung Cancer6 studies
- Cardiovascular Disease5 studies
- Type 2 Diabetes5 studies
- Bladder Cancer4 studies
- Esophageal Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.